News and reporting on cell-free DNA testing.
The group will validate Miraca's prototype extracellular vesicle isolation tool and antibody reagents using blood samples from breast and pancreatic patients.
The validation of its current CLIA testing comes as Biocept is in the early stages of expanding to provide kit versions of its liquid biopsy tests.
The company has collected initial evidence for an algorithmic method to predict immunotherapy response, and is studying its technology in treatment monitoring.
The Irvine, California-based firm said its "Revolution" system offer recovery rates of 70 to 90 percent across a wide range of liquid sample volumes.
The Boston-based company is working to make its extracellular vesicle detection technology more widely available for research and biomarker discovery.
